2025-05-13 - Analysis Report
Okay, here's a report summarizing the analysis of Teva Pharmaceutical Industries Ltd ADR (TEVA), based on the data you provided.

## Teva Pharmaceutical Industries Ltd ADR (TEVA) Analysis

### 1. Performance vs. S&P 500 (VOO)

*   **Ticker:** TEVA
*   **Company Overview:** Teva Pharmaceutical Industries Ltd ADR is a global pharmaceutical company specializing in generic and specialty medicines.
*   **TEVA Cumulative Return:** 66.77%
*   **VOO Cumulative Return:** 93.97%
*   **Return Discrepancy:** -27.2%
*   **Relative Discrepancy:** 68.2 (This indicates the current discrepancy is in the upper range of historical discrepancy, suggesting TEVA is currently underperforming VOO relative to its historical performance).

**Alpha/Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha   | Beta   | Cap(B) |
|------------|--------|-------|---------|--------|--------|
| 2015-2017  | -43.0% | 58.5% | -75.0% | 0.1 | 23.2  |
| 2016-2018  | -41.0% | 70.4% | -62.0% | -0.0 | 18.9  |
| 2017-2019  | -17.0% | 70.4% | -51.0% | -0.3 | 12.0  |
| 2018-2020  | -1.0%  | 70.4% | -31.0% | -0.2 | 11.8  |
| 2019-2021  | -23.0% | 58.4% | -83.0% | -0.2 | 9.8   |
| 2020-2022  | 26.0%  | 74.8% | 18.0%  | -0.3 | 11.2  |
| 2021-2023  | 38.0%  | 74.8% | 18.0%  | -1.0 | 12.8  |
| 2022-2024  | 123.0% | 74.8% | 102.0% | -0.9 | 27.0  |
| 2023-2025  | 76.0%  | 76.0% | 44.0%  | -0.1 | 22.0  |

**Analysis:**

*   **Underperformance:** TEVA has underperformed the S&P 500 over the specified period.
*   **Alpha & Beta:** The Alpha values are mostly negative, indicating that the investment is not performing well compared to the benchmark index, while the Beta values are around 0. This indicates the price is not volatile with respect to the market.
*   **CAGR & MDD:** The CAGR fluctuated year-over-year. High MDD values suggest significant potential for losses.

### 2. Recent Stock Price Movements

*   **Current Price:** \$17.96
*   **Previous Close:** \$16.93
*   **Change:** 6.08%
*   **5-day Moving Average:** 17.336
*   **20-day Moving Average:** 15.323
*   **60-day Moving Average:** 15.5667

**Analysis:**

*   **Price Increase:** The stock price has experienced a significant increase (6.08%) compared to the previous close, indicating a strong short-term positive movement.
*   **Moving Averages:** The current price is above all three moving averages, suggesting a short-term upward trend.  The 5-day MA is above the 20-day MA, which is also above the 60-day MA, reinforcing this bullish signal.

### 3. Technical Indicators

*   **Market Risk Indicator (MRI):** 0.3676 (Low Risk)
*   **RSI:** 78.61 (Overbought)
*   **PPO:** 2.3383
*   **Recent Relative Divergence Change (20-day):** 5.3 (Positive - Short-Term Increase)
*   **Expected Return:** -39.9%

**Analysis:**

*   **MRI:** The MRI suggests low market risk, but it's important to consider this in conjunction with other indicators.
*   **RSI:** The RSI value indicates that TEVA is currently overbought, which could suggest a potential pullback in the near term.
*   **PPO:** The PPO being positive suggests an upward trend.
*   **Relative Divergence:** The positive change in relative divergence confirms a recent short-term upward trend in performance relative to the benchmark.
*   **Expected Return:**  A negative expected return suggests that, based on the model, long-term returns are expected to underperform the S&P 500.
*   **Volatile Issues:**  The price change of 6.08% is quite large, suggesting a potentially significant event or news driving the price action.

### 4. Recent News & Significant Events

*   **2025-05-12:** Major business developments, regulatory changes, or market events.
*   **2025-05-09:** Analyst discussion of recent performance and outlook.
*   **2025-05-11:** Notable stock volatility influenced by recent news.
*   **2025-05-13:** Market experts highlighting both risks and opportunities.

**Analysis:**

*   **Recent Volatility:** The news indicates recent events are influencing the stock's performance, leading to volatility.
*   **Important Developments:** Pay close attention to any announcements from Teva related to business developments, regulatory changes, or earnings.

### 5. Recent Earnings Analysis

| 날짜       | EPS   | 매출      |
|------------|-------|-----------|
| 2025-05-07 | 0.19  | 3.89 B$   |
| 2024-11-06 | -0.39 | 4.33 B$   |
| 2024-07-31 | -0.75 | 4.16 B$   |
| 2024-05-08 | -0.12 | 3.82 B$   |
| 2025-05-07 | -0.12 | 3.82 B$   |

**Analysis:**

*   **Mixed Performance:** The EPS data is mixed, with some quarters showing positive EPS and others negative.
*   **Revenue Fluctuation:** Revenue has fluctuated over the past few quarters. The most recent quarter shows an improvement in EPS.

### 6. Financial Information

| Quarter    | Revenue  | Profit Margin |
|------------|----------|---------------|
| 2025-03-31 | \$3.89B  | 48.24%        |
| 2024-12-31 | \$4.23B  | 50.15%        |
| 2024-09-30 | \$4.33B  | 49.60%        |
| 2024-06-30 | \$4.16B  | 48.61%        |
| 2024-03-31 | \$3.82B  | 46.37%        |

| Quarter    | Equity   | ROE       |
|------------|----------|-----------|
| 2025-03-31 | \$6.26B  | 3.42%     |
| 2024-12-31 | \$5.37B  | -4.04%    |
| 2024-09-30 | \$6.07B  | -7.21%    |
| 2024-06-30 | \$6.36B  | -13.30%   |
| 2024-03-31 | \$7.28B  | -1.91%    |

**Analysis:**

*   **Revenue Trend:**  Revenue has generally been in the \$3.8B - \$4.3B range, showing some fluctuation.
*   **Profit Margin:** Profit margins have been relatively consistent, staying around 46%-50%.
*   **Equity & ROE:** Equity has fluctuated, and ROE has been mostly negative, indicating that the company has struggled to generate profits from its equity base. The recent quarter shows a return to positive ROE.

### 7. Overall Summary

Based on the provided data, TEVA presents a mixed picture:

*   **Underperformance:** TEVA has underperformed the S&P 500 over the historical period examined.
*   **Recent Positive Momentum:** There's been a recent surge in the stock price, supported by positive moving average indicators and recent divergence.
*   **Overbought Condition:** The RSI suggests the stock may be overbought in the short term.
*   **Earnings Concerns:** While revenue is stable, earnings have been inconsistent, and ROE has been mostly negative until recently.
*   **Market Uncertainty:** Recent news indicates volatility and significant developments are affecting the stock.
*   **Long-Term Outlook:** The expected return is negative, suggesting potential underperformance compared to the S&P 500 over the long term.

**Recommendation:**

Given the mixed signals, a cautious approach is warranted. Investors should:

*   **Monitor News:**  Stay informed about company announcements and news events that could impact the stock price.
*   **Assess Risk Tolerance:** The potential for short-term pullback due to the overbought condition should be considered.
*   **Review Financials:** Closely examine upcoming earnings reports and financial statements to assess the company's progress in improving profitability and ROE.
*   **Consider Diversification:** Given the negative expected return, consider diversifying your portfolio to reduce risk.

This analysis is based solely on the provided data and does not constitute financial advice.  Consult with a qualified financial advisor before making any investment decisions.
